Get the Stockscreener App
4.02
1.23%
-0.05
Pre-market:
3.95
-0.07
-1.74%
Protara Therapeutics Inc stock is traded at $4.02, with a volume of 206.68K.
It is down -1.23% in the last 24 hours and down -8.01% over the past month.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
See More
Previous Close:
$4.07
Open:
$4.08
24h Volume:
206.68K
Relative Volume:
0.09
Market Cap:
$147.81M
Revenue:
-
Net Income/Loss:
$-42.05M
P/E Ratio:
-1.4255
EPS:
-2.82
Net Cash Flow:
$-35.26M
1W Performance:
+2.55%
1M Performance:
-8.01%
6M Performance:
+113.83%
1Y Performance:
+10.14%
1-Day Range:
$3.965
$4.12
1-Week Range:
$3.65
$4.20
52-Week Range:
$1.595
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
Name
Protara Therapeutics Inc
Sector
Industry
Phone
646-844-0337
Address
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
4.02 | 147.81M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-23 | Resumed | Guggenheim | Buy |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Feb-17-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Jul-29-20 | Initiated | Guggenheim | Buy |
Protara Therapeutics Inc Stock (TARA) Latest News
Analysts Set Expectations for TARA Q1 Earnings - Defense World
Protara Therapeutics (NASDAQ:TARA) Coverage Initiated by Analysts at Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Protara Therapeutics (TARA) with Outperform Recommendation - Nasdaq
HC Wainwright Issues Positive Forecast for TARA Earnings - Defense World
What is HC Wainwright’s Forecast for TARA FY2029 Earnings? - Defense World
Protara Therapeutics’ (TARA) Buy Rating Reiterated at HC Wainwright - Defense World
Protara Therapeutics’ TARA-002 Shows Promising Efficacy and Safety in HR-NMIBC, Earning Buy Rating - TipRanks
H.C. Wainwright maintains Buy rating on Protara stock, $23 target By Investing.com - Investing.com UK
Protara Therapeutics (NASDAQ:TARA) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Protara Therapeutics: Q4 Earnings Snapshot - Midland Daily News
Protara Therapeutics Reports Progress and Financial Results - TipRanks
Protara Therapeutics shares rise on narrower Q4 loss By Investing.com - Investing.com South Africa
Protara Therapeutics shares rise on narrower Q4 loss - Investing.com
Protara Therapeutics reports Q4 EPS (48c) vs (90c) last year - TipRanks
Protara Therapeutics: Q4 Earnings Snapshot -March 05, 2025 at 08:21 am EST - Marketscreener.com
Protara Therapeutics, Inc. SEC 10-K Report - TradingView
Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - TradingView
Can Protara's 72% Response Rate in Bladder Cancer Trial Transform Treatment Landscape? - StockTitan
Protara Therapeutics (TARA) Projected to Post Quarterly Earnings on Wednesday - Defense World
Protara Therapeutics Stock Doubles On Promising Bladder Cancer Trial Data: Retail Buzz Spikes - MSN
Protara Therapeutics (NASDAQ:TARA) Stock Price Down 4%Here's What Happened - MarketBeat
Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
Rare Disease Biotech Protara Sets Investor Presentation: What's Next for TARA Pipeline? - StockTitan
Protara Therapeutics (NASDAQ:TARA) Stock Price Down 4% – Should You Sell? - Defense World
Certain Pre-Funded warrants of Protara Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2025. - Marketscreener.com
Certain Common Warrants of Protara Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-FEB-2025. - Marketscreener.com
Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Reviewing Protara Therapeutics (NASDAQ:TARA) and Palisade Bio (NASDAQ:PALI) - Defense World
Exclusive Healthcare Insights: Protara Therapeutics Takes Center Stage at Major Oppenheimer Conference - StockTitan
Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Significant Drop in Short Interest - MarketBeat
Protara Therapeutics (NASDAQ:TARA) vs. Cardiff Oncology (NASDAQ:CRDF) Head-To-Head Review - Defense World
Geode Capital Management LLC Purchases 29,514 Shares of Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Protara Highlights Recent Updates and Anticipated 2025 Milestones - The Manila Times
Protara Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Increase in Short Interest - MarketBeat
XTX Topco Ltd Buys New Position in Protara Therapeutics, Inc. (NASDAQ:TARA) - Defense World
Velan Capital Investment Management LP Increases Stake in Protara Therapeutics Inc - GuruFocus.com
Flatiron-based drug company raises $100M for cancer treatment - Crain's New York Business
Protara Therapeutics: Rising From The Ashes (NASDAQ:TARA) - Seeking Alpha
Protara Therapeutics Raises $100M in Stock Offering - TipRanks
Protara Announces Closing of $100 Million Public Offering - GlobeNewswire
SEC Form 424B5 filed by Protara Therapeutics Inc. - Quantisnow
Protara Therapeutics Secures Massive $100M Public Offering to Advance TARA-002 Development - StockTitan
Protara Therapeutics: Carving New Roads In Bladder Cancer (TARA) - Seeking Alpha
Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst - Seeking Alpha
Protara Therapeutics Inc Stock (TARA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):